ARID1A and neoplasm: ARID1A mutations have been associated with high levels of tumor-infiltrating lymphocytes and PD-L1 expression in CCC (4), but it is still debated whether ARID1A mutations can serve as a biomarker for immune checkpoint inhibitor treatment (5).